BLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal.
The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could...
According to the CEO of NVDA, the next big revolution is coming into biotech. Biology will be engineered and therefore will compound exponentially. Now might be a good time to enter this field.
If you haven`t bought SRPT here:
Then you need to know that there is a Massive catalyst coming!
Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November.
This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17.
Some...
Last year in Autumn we had this buyout rumor. I remember back then Exact Sciences said to approach Invitae about a potential merger.
Now, NVTA, Invitae Corporation, is trading at an all-time low, $0.62.
Some deals take one or two years to perfect, and we don't know what caused the recent price decrease.
Sometimes this happens before an announcement.
Today,...
GRI Bio recently underwent a 1/30 split on April 24th, accompanied by a merger/restructure of Vallon Pharmaceuticals. The stock price immediately tanked approx. 50% in the following days. The price has held above the low of $5.50 on April 26th for over a month. Based on past performance, this stock has a tendency to jump 30 to >200% in a single day. GRI Bio has...
ETON jumped on a big earnings report a week ago. This small cap biotechology
company is making big money and traders responded. It has now experienced
a standard 0.5 Fib level retracement pullback and traders early in the jump
take profit. At this level new buyers have equilibrated with those selling their
shares and taking profit. The ZL MACD lines are...
If you haven`t bought the Double Bottom on QSI:
Then it seems that there is a potential reversal from this level.
Earnings were a beat, but too small to justify the recent breakout.
The Elliot Waves chart pattern indicates a price target of $2.93.
Looking forward to read your opinion about it!
NKTR is due for earnings on August 8th. The price from the opening bell on the 7th
pump nearly 100% to over $1.00 and then faded by a couple of cents.
The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity
action into a high tight type bull falg which is often considered to be predictive
of another leg up of similar magnitude. I will be...
If you haven`t bought the Double Bottom:
Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in.
Importance of Protein Sequencing:
- Understanding Cellular Processes: Proteins...
XYNI is now ready to reverse long. I analyze this because ZYXI has dropped
from overvalued and overbought through the fair value zone into undervalued
territory in three trading days by viewing the anchored VWAP bands and the
volume profile, The mean VWAP and POC line are confluent at 7.25. This is the
logical first target. The MACD lines are negative 4X the...
Nascent Biotech is reportedly closing in on phase I trial completion. I am interested to see if it pulls back and how it interacts with the moving averages.
www.nascentbiotech.com
I believe that CRSP (Crispr Therapeutics) is about to undergo a severe correction soon.
I scaled into this stock during the latter part of 2022 and the first part of 2023 and it is up nearly 70% and has generated about 40% of pure alpha for me relative to the SPX.
So this has been an amazing performer for my total portfolio.
I believe this run may be nearing a...
FLMD had earnings in May with positive earnings beating the expectation of analysts that
it would continue to lose quarter after quarter. Investors and traders have reacted with a
80% run-up in the month after those earnings. On the 30-minute chart besides the consistent
uptrend with minor corrections, what stands out for me is the increasing volumes...
Based on Phase 2 data evaluation we could expect a positive outcome. Information sound good so far. THese kind of news often cause a wild rally on the day. Maybe two days. But generally they dont last long. Depends on the news of course.
But I would expect a pop on this on monday or tuesday. Maybe interesting for a short trade.
AUTL on the one-hour chart had a spontaneous parabolic move without a catalyst as best as
I can tell. Earnings ten days ago were decent but nothing special. AUTL as a biotech firm is
losing cash just not as much as analysts predicted. In the parabolic move very few shares
were traded between $2.00 and $2.40 as per the volume profile Overall a massive volume...
Biotech stocks can make huge moves, and this one is no exception.
TGTX more than doubled in a month and is showing no signs of slowing down.
Slower-trending, blue chip stocks tend to ride their 50-day moving average (red line on chart) on the way up.
Stronger stocks tend to hold their 21-day moving average (blue line).
But with high-flying honey badger stocks...
VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked)
approximately a doubling of the shart price in the next year. Like many low share priced
biotechnology stocks the price is based on perceived future earnings which can be affected
by favorable FDA process, or well-received research at industry conferences and changing...
BlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time
but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks
since earnings which is about 500% annualized. GO BLUE.
On the daily chart, price was above VWAP and consolidating much of last fall then dropped
this YTD until the earnings...
